The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...
A comprehensive study published in the journal of BMJ Rheumatic & Musculoskeletal Diseases focused on the prevalence and risk ...
Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Explore the efficacy and safety of first-line targeted synthetic DMARDs in rheumatoid arthritis patients with chronic kidney ...
The excess payments Medicare Advantage plans receive for higher risk scores may be more influenced by differences in coding practices rather than actual differences in disease burden between MA and ...
Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.
Ardelyx to receive $5 million milestone payment from Fosun Pharma following approvalWALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded ...
There used to be no specific treatments for heart failure with preserved ejection fraction, but recent clinical trials show ...
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines ...
Revelation Biosciences (REVB) announced dosing of the first patient in the PRIME, or PReconditioning IMmunostimulatory Evaluation, Phase 1b ...
Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products ...
As the world's first and currently only approved phosphate absorption inhibitor, Tenapanor Hydrochloride Tablets has been officially approved in China, ushering in a new era of multi-mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results